Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
Ann Oncol. 2017 Sep 1;28(9):2057-2066. doi: 10.1093/annonc/mdx280.
The ESMO Designated Centres (ESMO-DCs) of Integrated Oncology and Palliative Care (PC) Incentive Programme has grown steadily. We aimed to characterise the level of PC clinical services, education and research at ESMO-DCs.
We sent all 184 ESMO-DCs an electronic survey consisting of 78 questions examining the DC characteristics, palliative care clinical programme (structure, processes, and outcomes), primary PC delivery by oncologists, education, research and attitudes and beliefs towards the ESMO-DC programme.
The response rate was 83% (152/184). 115 (76%) ESMO-DCs were from Europe, 87 (57%) were tertiary care centres. 136 (90%) had inpatient consultation teams, 135 (89%) had outpatient PC clinics, 107 (71%) had dedicated acute care beds, and 75 (50%) offered community-based PC. An estimated 70% (interquartile range [IQR] 28-80%) of patients with advanced cancer had a PC consultation before death, occurring 90 days before death (median, IQR 40-150 days) for outpatients and 21 days (IQR 14-45 days) for inpatients. 59 (39%) offered PC fellowship programme; 47 (32%) had mandatory PC rotations for oncology fellows. Ninety-nine (65%) had double-boarded palliative oncologists. 118 (78%) of the ESMO-DCs reported that routine symptom screening was offered in the oncology clinic and 30% of patients had documented end-of-life discussions by their oncologists. Most centres (>80%) perceived the ESMO-DC programme to increase their status.
The ESMO-DCs had a high level of PC infrastructure and provided access to a large proportion of patients with advanced cancer. The survey supports that the 13 criteria required for ESMO designation set a robust framework for integration, stimulated investment of resources into some palliative care programmes prior to accreditation, and raised the interest about palliative care among clinicians, trainees and patients.
ESMO 指定综合肿瘤与姑息治疗中心(ESMO-DC)激励计划的数量稳步增长。我们旨在描述 ESMO-DC 的姑息治疗临床服务、教育和研究水平。
我们向所有 184 个 ESMO-DC 发送了一份电子调查问卷,其中包含 78 个问题,用于考察 DC 特征、姑息治疗临床项目(结构、流程和结果)、肿瘤医生提供的主要姑息治疗、教育、研究以及对 ESMO-DC 计划的态度和信念。
应答率为 83%(152/184)。115 个(76%)ESMO-DC 来自欧洲,87 个(57%)是三级治疗中心。136 个(90%)有住院会诊团队,135 个(89%)有姑息治疗门诊,107 个(71%)有专门的急性护理病床,75 个(50%)提供社区姑息治疗。据估计,70%(四分位间距 [IQR]28-80%)的晚期癌症患者在死亡前有姑息治疗咨询,门诊患者死亡前咨询发生在 90 天(中位数,IQR40-150 天),住院患者为 21 天(IQR14-45 天)。59 个(39%)提供姑息治疗研究员计划;47 个(32%)有肿瘤学研究员强制性姑息治疗轮岗。99 个(65%)有双证姑息肿瘤医生。118 个(78%)的 ESMO-DC 报告在肿瘤诊所提供常规症状筛查,30%的患者在肿瘤科医生处有记录的临终讨论。大多数中心(>80%)认为 ESMO-DC 计划提高了他们的地位。
ESMO-DC 拥有高水平的姑息治疗基础设施,并为大量晚期癌症患者提供服务。调查结果支持 ESMO 指定所需的 13 项标准为整合提供了一个稳健的框架,在获得认证之前刺激了对一些姑息治疗项目的资源投入,并提高了临床医生、受训者和患者对姑息治疗的兴趣。